Evolving Therapy in Relapsed Myeloma

Cancer therapy & Oncology International Journal
doi 10.19080/ctoij.2016.02.555596
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Juniper Publishers

Related search

Ixazomib in the Treatment of Relapsed Multiple Myeloma

Medical Council
2018English

Arsenic Trioxide-Based Therapy in Relapsed/Refractory Multiple Myeloma Patients: A Meta-Analysis and Systematic Review

OncoTargets and Therapy
OncologyPharmacology
2014English

Carfilzomib for Relapsed or Refractory Multiple Myeloma

The Lancet Oncology
Oncology
2018English

Evolving Therapeutic Role of Bisphosphonates in Multiple Myeloma

British Journal of Cancer
Cancer ResearchOncology
2005English

Cardiovascular Events During Carfilzomib Therapy for Relapsed Myeloma: Practical Management Aspects From Two Case Studies

Hematology
Hematology
2017English

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

European Journal of Medical Research
Medicine
2010English

Toxicity-Reduced, Myeloablative Allograft Followed by Lenalidomide Maintenance as Salvage Therapy for Refractory/Relapsed Myeloma Patients

Bone Marrow Transplantation
TransplantationHematology
2012English

Characterisation and Prognostic Impact of Immunoparesis in Relapsed Multiple Myeloma

British Journal of Haematology
Hematology
2020English

A Phase I Trial of Flavopiridol in Relapsed Multiple Myeloma

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy